CHM Cannabis
Home > Boards > US OTC > Medical - Healthcare >

Derma Sciences, Inc (DSCI)

Add DSCI Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/12/2017 8:31:14 AM - Followers: 16 - Board type: Free - Posts Today: 0

                                                                                         Derma Sciences has achieved a key
MEDIHONEY® sales milestone

                                                                                          Derma Sciences Raises $29 Million in Private Placement Financing




Web Site: http://www.dermasciences.com/                    (Multiple) Contact Page:  http://www.dermasciences.com/contact/
     [ eLearning Portal ]:  Inc Webinar Series & Product Demonstrations  http://www.dermasciences.com/elearning-portal/

Corporate Address:
214 Carnegie Center Suite 300, Princeton, NJ 08540.          Phone 609-514-4744            Tax ID: 23-2328753

Investor Presentations:

Management Team: Edward J Quilty CEO. / John E Yetter VP & CFO.
Robert C Cole Exec VP Sales  /  Frederic Eigner Exec VP Operations  /  Barry Wolfenson Exec VP Marketing & Developement

SEC Filingshttp://www.ir.dermasciences.com/profiles/investor/secxml.asp?f=1&BzID=1109&to=sc&Nav=0&LangID=1&s=302     

Request Infohttp://www.ir.dermasciences.com/profiles/investor/RequestInfo.asp?f=1&BzID=1109&to=ri&Nav=0&LangID=1&s=302     

Transfer Agent: StockTrans Inc.  telephone number 800-733-1121.     Independent Auditor: KPMG, LLP  telephone number 201-307-7000


Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into 5 categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international market.

Key Products: MEDIHONEY
(wound and burn dressings)            XTRASORB(super absorbent polymer-based dressings)
                                           BIOGUARD (barrier dressings)                   
 ALGICELL AG    (anti-microbial 1.4 % silver) 
                          DSDSC127(angiotensin analog) Key Product Under Developement  
Silverseal®    line of specialty burn dressings.

MEDIHONEY  /  Medicine from A Flowering Manuka Bush And A Honey Bee.  New Zealand.


Line Of Credit  [ From a US Lender ]:   At March 31, 2011, the effective interest rate was 5.75%, the outstanding balance was $2,374,998 and availability was $1,652,848. 

 At March 31, 2011 and December 31, 2010, we had cash and cash equivalents of $827,253  Cash & Cash Equivalents$827,253     


We generated a net loss of $547,032, or $0.08 per share (basic and diluted), in 2011 compared to a net loss of $578,689, or $0.10 per share (basic and diluted), in 2010

Based on current forecasts, a $1,000,000 Medihoney sales related milestone payment is anticipated in the next twelve months.

Working capital increased $663,127 at March 31, 2011 to $10,607,056 from $9,943,929 at December 31, 2010.  This increase reflects our positive cash flow from operations together with the funds received from the warrant and stock option exercises during the quarter.  Management believes that this level of working capital is sufficient to support our existing operations.


Outstanding Shares: 6,743,382
As of May 10, 2011     up to 2,903,492 shares of our common stock are potentially issuable
upon the conversion, exercise or vesting of outstanding convertible preferred stock, warrants and options ("dilutive securities"). 

                                                       {C}{C}{C}{C}  {C}{C}{C}{C}{C}
 As of May 10, 2011, up to 2,903,492 shares of our common stock are potentially issuable upon the conversion, exercise or vesting of outstanding convertible preferred stock, warrants and options ("dilutive securitie{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{C}{cke_protected
CHM Cannabis
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#181   The bid $6.90 support is ridiculous here..... over Mistr Tommy 01/12/17 08:31:13 AM
#180   I like her here akamaii 07/17/15 07:54:56 AM
#179   DSCI rated outperform. Good entry point right here. T695 05/17/15 04:35:47 PM
#178   7:16AM Derma Sciences sees 2013 revenue of approx surf1944 01/16/14 12:19:49 PM
#177   9:20AM Derma Sciences enters the skin substitute market surf1944 01/14/14 11:35:32 AM
#176   7:31AM Derma Sciences announces published research concluded total surf1944 06/12/13 08:06:46 AM
#175   7:30AM Derma Sciences on track to begin phase surf1944 10/22/12 08:43:37 AM
#174   7:30AM Derma Sciences acquires global long-term exclusive rights surf1944 07/13/12 08:25:26 AM
#173   You did a great job and no need. Penny Roger$ 05/09/12 05:00:13 AM
#172   Hi everybody. Looking good now. No mod since PoemStone 05/08/12 04:27:17 PM
#171   ~ Monday! $DSCI ~ Earnings posted, pending or Penny Roger$ 03/24/12 11:21:01 PM
#170   Derma Sciences meeting with FDA supports initiation of mlkrborn 03/06/12 11:29:57 AM
#169   http://www.sec.gov/Archives/edgar/data/806085/000090951812000032/mm02-0812derma_ sidedraft 02/08/12 10:30:22 PM
#168   11-11-11 Conference call is coming up. PoemStone 11/05/11 08:35:31 PM
#167   DSCI to Present at the Lazard Capital Markets PoemStone 11/04/11 11:10:56 AM
#166   CompanyUpdate & 3rd Quarter ConferenceCall 11-11-11: PoemStone 11/03/11 10:07:11 AM
#165   I agree. PoemStone 10/13/11 02:30:03 PM
#164   THE best wound care product you can buy. 42Degrees 10/13/11 02:29:11 PM
#163   Derma Sciences Launches MEDIHONEY® Gel at the Fall PoemStone 10/13/11 02:21:59 PM
#162   Studies demonstrate the benefit of BIOGUARD over Kerlix® PoemStone 10/11/11 08:34:32 PM
#161   Chart: PoemStone 09/26/11 01:09:47 PM
#160   Jefferies 2011 Global Healthcare Conference PoemStone 09/26/11 11:26:57 AM
#159   Derma Sciences to Present at the Rodman & PoemStone 09/07/11 01:49:59 PM
#158   Thanks! Glad to be able to help out =D 42Degrees 09/06/11 01:12:44 PM
#157   The Moderators on this board are being responsible PoemStone 09/05/11 09:02:44 AM
#156   Welcome 42Degrees as Assistant Moderator! PoemStone 09/05/11 08:59:06 AM
#155   I can also personally attest that Medihoney was 42Degrees 09/02/11 11:08:15 PM
#154   Everything is way on track here. PoemStone 08/16/11 05:36:25 PM
#153   Derma Sciences Reports Second Quarter Operating Results: PoemStone 08/16/11 11:25:39 AM
#152   Derma Sciences today is in the strongest position PoemStone 08/16/11 11:23:21 AM
#151   10-Q / Conference Call August 16th 2011: PoemStone 08/10/11 11:13:28 AM
#150   Derma Sciences has achieved a key MEDIHONEY® sales milestonehttp://ih.advfn.com/ PoemStone 08/08/11 02:48:17 PM
#149   images.investorshub.advfn.com/images/uploads/2011/6/2/vbugzDSCI_9.jpg[/ch PoemStone 08/07/11 10:44:39 AM
#148   "Eight videos including Derma Sciences Commitment to Advanced PoemStone 08/02/11 09:42:41 AM
#147   MEDIHONEY Hydrogel dressing will be the first in PoemStone 08/01/11 01:53:35 PM
#146   Drug Administration 510(k) clearance for its patented MEDIHONEY® PoemStone 08/01/11 01:52:55 PM
#145   MEDIHONEY®, XTRASORB®, BIOGUARD® and ALGICELL® Ag. These PoemStone 07/30/11 01:37:49 PM
#144   If you like reading [a prospectus] Have at PoemStone 07/22/11 01:24:47 PM
#143   BIOGUARD [Barrier Dressings] gets a big nod: PoemStone 07/20/11 10:01:26 AM
#142   Chart looks good for a step uP. PoemStone 07/19/11 05:18:12 PM
#141   Ok skipper66. DSCI will be right here for PoemStone 07/15/11 11:07:44 AM
#140   Poemstone, can't reply privately. skipper66 07/15/11 11:00:17 AM
#139   Hi skipper66. I agree with you. DSCI has PoemStone 07/15/11 09:42:52 AM
#138   Not too many seem to follow DSCI (yet). skipper66 07/15/11 08:15:38 AM
#137   DSCI is acting like a $10 stock & PoemStone 07/06/11 03:31:43 PM
#136   Raised 29 million in Private Placement. PoemStone 06/20/11 10:39:04 AM
#135   DSCI. The url's on the iBox are now PoemStone 06/19/11 08:03:18 PM
#134   Investor Presentation has it all. PoemStone 06/16/11 04:52:40 PM
#133   Employees: 195. Employee growth: 12.1%. Year 2010. PoemStone 06/11/11 03:12:02 PM
#132   Read the iBox. Derma Sciences has wonderful products. PoemStone 06/10/11 10:38:16 PM